Systemic consequences of intestinal inflammation

Papadakis, Konstantinos A.; Abreu, María T.

doi:10.1007/0-387-25808-6_12

Cited by 2 publications

(2 citation statements)

References 174 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IL-6 is a cytokine known to cause side effects, such as fever, hypotension, myalgia and respiratory failure (46). In addition to T cells, macrophages are a typical cell subset that produce IL-6 (47). In a mouse model, the severity of CRS was reduced when monocytes depleted, which provided the major source of IL-1 and IL-6 or can block IL-6 receptor with tociizumab, suggesting that IL-6 inhibitors or anti-IL-6 receptor antibodies may reverse the syndrome (48).…”

Section: Discussionmentioning

confidence: 99%

“…In a mouse model, the severity of CRS was reduced when monocytes depleted, which provided the major source of IL-1 and IL-6 or can block IL-6 receptor with tociizumab, suggesting that IL-6 inhibitors or anti-IL-6 receptor antibodies may reverse the syndrome (48). Recently, two independent trials from two research teams at the San Rafael Institute of Science and the Memorial Sloan Kettering Cancer Center (MSKCC) demonstrated that CRS is triggered by the inflammatory molecule IL-1 (46,47). Anakinra is an IL-1 inhibitor that can be combined with CAR T-cell therapy and is effective in managing CRS and neurotoxicity (49).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Dual specific CD19/CD22‑targeted chimeric antigen receptor T‑cell therapy for refractory diffuse large B‑cell lymphoma: A case report

Huang

Zhang

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Clinical trials of chimeric antigen receptors (CARs) targeting CD19 have produced impressive results in hematological malignancies, including diffuse large B-cell lymphoma (DLBCL). However, a notable number of patients with DLBCL fail to achieve remission after CD19 CAR T-cell therapy and may therefore require a dual targeted CAR T-cell therapy. A 31-year-old man with refractory DLBCL was assessed in the present case report. The patient was treated with sequential infusion of single CD19 CAR T cells followed by dual CD19/CD22-targeted CAR T cells. The outcome was that the patient achieved partial remission after the first single CD19 CAR T-cell infusion and complete remission after the dual CD19/CD22-targeted CAR T-cell infusion. Grade 1 cytokine release syndrome (CRS) was observed after the single CD19 CAR T-cell infusion, while grade 3 CRS and hemophagocytic syndrome were observed after the dual targeted CAR T-cell infusion, but these adverse effects alleviated after the treatments. To the best of our knowledge, the present case report is the first to describe the successful application of dual CD19/CD22-targeted CAR T-cell therapy for the treatment of refractory DLBCL. The report suggests that dual CD19/CD22-targeted CAR T-cell therapy may represent a promising option for the treatment of refractory DLBCL; however, caution should be taken due to potential CRS development.

show abstract

Section: Discussionmentioning

confidence: 99%